newsfilter
← Latest News
GlobeNewswire·

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payment